Buer N. Li

95 Yong An Road
Beijing, 100050, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Simvastatin Alleviates ConA-Induced Autoimmune Hepatitis by Inhibiting CD4+ T Cell Activation via Calcium-NFATC3 Pathway.

Simvastatin Alleviates ConA-Induced Autoimmune Hepatitis by Inhibiting CD4+ T Cell Activation via Calcium-NFATC3 Pathway.

Journal: Inflammation

Published: October 06, 2025

Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis.

Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis.

Journal: BMC gastroenterology

Published: September 02, 2025

Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.

Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.

Journal: Journal of gastroenterology

Published: August 11, 2025

SLAMF7 promotes TCRαβ+ double negative T cell antitumor activity through enhancing glutamine metabolism.

SLAMF7 promotes TCRαβ+ double negative T cell antitumor activity through enhancing glutamine metabolism.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 08, 2025

Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients.

Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients.

Journal: European journal of gastroenterology & hepatology

Published: May 09, 2025

Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients.

Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients.

Journal: European journal of gastroenterology & hepatology

Published: May 09, 2025

Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.

Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.

Journal: Journal of clinical and translational hepatology

Published: October 11, 2024

IFITM1 aggravates ConA-Induced autoimmune hepatitis by promoting NKT cell activation through increased AMPK-Dependent mitochondrial function.

IFITM1 aggravates ConA-Induced autoimmune hepatitis by promoting NKT cell activation through increased AMPK-Dependent mitochondrial function.

Journal: International immunopharmacology

Published: October 10, 2024

Horizontal sound localization in presence of noise in normal-hearing young adults

Horizontal sound localization in presence of noise in normal-hearing young adults

Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Published: April 01, 2024

Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena.

Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena.

Journal: Therapeutic advances in gastroenterology

Published: August 16, 2023

The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.

The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.

Journal: Hepatology communications

Published: May 23, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026